Treatment for ADHD is designed to help refocus the brain, much like glasses are used to help near-sighted children see better. The Monarch eTNS System helps to regulate the brain areas linked to ADHD symptoms via the trigeminal nerve, the body's thickest nerve The trigeminal nerve has branche...
NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company’s lead product is the Monarch eTNS System, which is the first non-drug t...
The results will establish whether eTNS is effective and safe as a novel non-pharmacological treatment for ADHD. Trial registration: ISRCTN82129325 on 02/08/2021, https://doi.org/10.1186/ISRCTN82129325.doi:10.1186/s12888-024-05650-1Rubia, Katya...
NeuroSigma, Inc., a bioelectronic medical device company, and Ignis Therapeutics, a life science company focusing on the central nervous system therapies, jointly announced that Ignis Therapeutics has acquired the exclusive license in China of NeuroSigma
“NeuroSigma’s Monarch eTNS System was the first non-drug treatment for pediatric ADHD cleared by the FDA. Starting April 1st of this year, payers will be able to use these unique new HCPCS codes to establish coverage policies and payment decisions,” said Ian Cook, M.D...